May 04, 2013, 12.21 PM IST | Source: Moneycontrol.com

Aurobindo Pharma gets USFDA nod for prostate treatment drug

Aurobindo Pharma has got final approval from the US drug regulator to manufacture and market a generic version of Tamsulosin Hydrochloride capsules used to treat symptoms of enlarged prostate in men. It has also received approval to sell a copy of Clindamycin Palmitate Hydrochloride for oral solution used in bacterial infections in infants.

Moneycontrol Bureau

Aurobindo Pharma on Saturday said it has received final approval from the US Food and Drugs Administration to manufacture and market Tamsulosin Hydrochloride capsules in 0.4mg strength.

The drug is a generic version of Boehringer Ingelheim Pharmaceuticals' Flomax capsules and is indicated for the treatment of symptoms of an enlarged prostate in men.

The US market size of the product was around USD 244 million for the 12-months ended September 2012, Aurobindo said, citing IMS Health data.

Further, Aurobindo Pharma has also got final approval from US FDA to manufacture and market Clindamycin Palmitate Hydrochloride for oral solution in pediatric, 75mg (base)/5 ml strength.

Clindamycin Palmitate is a copy of Pharmacia & Upjohn's Cleocin and is indicated for treating serious infections caused by susceptible anaerobic bacteria in infants.

For 12-months ended September 2012, the US market size of the drug was around USD 57 million, the company said citing IMS Health data.

The Hyderabad headquartered company now has 190 ANDA approvals from the US drug regulator. These include 163 final and 27 tentative approvals.

Aurobindo Pharma shares closed at Rs 196.65 on NSE on Friday, down 1.4 percent.

Also Read: Bharti's stake sale to help ease debt burden, say experts

Aurobindo Pharm stock price

On April 17, 2014, Aurobindo Pharma closed at Rs 551.35, up Rs 3.35, or 0.61 percent. The 52-week high of the share was Rs 575.95 and the 52-week low was Rs 138.45.


The company's trailing 12-month (TTM) EPS was at Rs 31.05 per share as per the quarter ended December 2013. The stock's price-to-earnings (P/E) ratio was 17.76. The latest book value of the company is Rs 100.84 per share. At current value, the price-to-book value of the company is 5.47.

Set email alert for

ADS BY GOOGLE

Buy & sell politicians on Power Play
- the political stock exchange

Price Update

Narendra Modi

87181.65 2,280.94 2.69%

2976

Bought today

3492

Sold today

1.76%

User holding

video of the day

Chandra says satisfied with TCS' FY14, FY15 to be better

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.